{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:31:01Z","timestamp":1793327461077,"version":"4.5.0"},"reference-count":214,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.canlet.2026.218899","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:58:28Z","timestamp":1792508308000},"page":"218899","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Next-generation CAR-macrophage therapies: Design principles and advances in cancer treatment"],"prefix":"10.1016","volume":"662","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0179-1395","authenticated-orcid":false,"given":"Weihua","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songyue","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihui","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoya","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunli","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9528-0580","authenticated-orcid":false,"given":"He","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218899_bib1","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.canlet.2026.218899_bib2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12943-024-02032-9","article-title":"A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy","volume":"23","author":"Li","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2026.218899_bib3","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2114254","article-title":"Current updates on generations, approvals, and clinical trials of CAR T-cell therapy","volume":"18","author":"Asmamaw Dejenie","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.canlet.2026.218899_bib4","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1001\/jama.2024.28312","article-title":"Obecabtagene autoleucel for B-Cell acute lymphoblastic leukemia","volume":"333","author":"Bouchkouj","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.canlet.2026.218899_bib5","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12943-024-02079-8","article-title":"Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy","volume":"23","author":"Xia","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2026.218899_bib6","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T therapies in multiple myeloma: unleashing the future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.canlet.2026.218899_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2026.218240","article-title":"CAR-T cell exhaustion in cancer over the past decade: mitochondrial metabolism as a target for counteraction","volume":"639","author":"Si","year":"2026","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218899_bib8","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218899_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-026-02907-x","article-title":"Harnessing macrophage signaling pathways and scalable engineering for next-generation immunotherapies","volume":"11","author":"Paasch","year":"2026","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2026.218899_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202103258","article-title":"Nanocomplex-mediated in vivo programming to chimeric antigen Receptor-M1 macrophages for cancer therapy","volume":"33","author":"Kang","year":"2021","journal-title":"Adv Mater"},{"key":"10.1016\/j.canlet.2026.218899_bib11","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.canlet.2026.218899_bib12","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jconrel.2024.02.033","article-title":"Adoptive cell therapy for solid tumors beyond CAR-T: current challenges and emerging therapeutic advances","volume":"368","author":"Zhang","year":"2024","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.canlet.2026.218899_bib13","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s40364-024-00637-2","article-title":"CAR macrophages: a promising novel immunotherapy for solid tumors and beyond","volume":"12","author":"Lu","year":"2024","journal-title":"Biomarker Res."},{"key":"10.1016\/j.canlet.2026.218899_bib14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41590-023-01696-7","article-title":"CAR macrophages on a fast track to solid tumor therapy","volume":"25","author":"Abdin","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2026.218899_bib15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13045-020-00983-2","article-title":"Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions","volume":"13","author":"Zhang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2026.218899_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/cells11223692","article-title":"CAR-macrophages and CAR-T cells synergistically kill tumor cells in vitro","volume":"11","author":"Liu","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2026.218899_bib17","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s40164-024-00549-9","article-title":"The next frontier in immunotherapy: potential and challenges of CAR-macrophages","volume":"13","author":"Li","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2026.218899_bib18","article-title":"Bioengineer mesenchymal stem cell for treatment of glioma by IL-12 mediated microenvironment reprogramming and nCD47-SLAMF7 mediated phagocytosis regulation of macrophages","volume":"4","author":"Li","year":"2024","journal-title":"Explorations"},{"key":"10.1016\/j.canlet.2026.218899_bib19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.32604\/or.2023.042383","article-title":"Opportunities and challenges of CD47-targeted therapy in cancer immunotherapy","volume":"32","author":"Chen","year":"2023","journal-title":"Oncol. Res."},{"key":"10.1016\/j.canlet.2026.218899_bib20","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41591-025-03495-z","article-title":"CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial","volume":"31","author":"Reiss","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218899_bib21","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s00018-021-04089-x","article-title":"Tuning the ignition of CAR: optimizing the affinity of scFv to improve CAR-T therapy","volume":"79","author":"Duan","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.canlet.2026.218899_bib22","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.jcyt.2024.02.024","article-title":"Alternative target recognition elements for chimeric antigen receptor (CAR) T cells: beyond standard antibody fragments","volume":"26","author":"Nix","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.canlet.2026.218899_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008566","article-title":"Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity","volume":"12","author":"Shabaneh","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218899_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/biology12020287","article-title":"CAR based immunotherapy of solid Tumours-A clinically based review of target antigens","volume":"12","author":"Maher","year":"2023","journal-title":"Biology"},{"key":"10.1016\/j.canlet.2026.218899_bib25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40164-025-00621-y","article-title":"Mesothelin-targeted CAR-T cells secreting NKG2D-BiTEs exhibit potent efficacy against triple-negative breast cancer","volume":"14","author":"Saliu","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2026.218899_bib26","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1158\/1078-0432.CCR-19-2586","article-title":"Phase I\/II study of the mesothelin-targeted immunotoxin LMB-100 with nab-paclitaxel for patients with advanced pancreatic adenocarcinoma","volume":"26","author":"Alewine","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218899_bib27","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.stemcr.2022.12.012","article-title":"Generation of anti-GD2 CAR macrophages from human pluripotent stem cells for cancer immunotherapies","volume":"18","author":"Zhang","year":"2023","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.canlet.2026.218899_bib28","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/s41591-025-03513-0","article-title":"Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma","volume":"31","author":"Li","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218899_bib29","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/s41388-025-03332-0","article-title":"Human CSPG4-targeting CAR-macrophages inhibit melanoma growth","volume":"44","author":"Greiner","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2026.218899_bib30","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.stem.2024.03.018","article-title":"Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer","volume":"31","author":"Shah","year":"2024","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.canlet.2026.218899_bib31","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2147\/ITT.S291767","article-title":"Fibroblast activation protein (FAP)-Targeted CAR-T cells: launching an attack on Tumor Stroma","volume":"10","author":"Bughda","year":"2021","journal-title":"ImmunoTargets Ther."},{"key":"10.1016\/j.canlet.2026.218899_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113888","article-title":"In vivo FAP-CAR macrophages enhance chemotherapy and immunotherapy against pancreatic cancer by removing the fibrosis barrier","volume":"384","author":"Wang","year":"2025","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.canlet.2026.218899_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116604","article-title":"Targeting fibroblast activation protein with chimeric antigen receptor macrophages","volume":"230","author":"Mao","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.canlet.2026.218899_bib34","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s43018-023-00709-6","article-title":"Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial","volume":"5","author":"Bagley","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.canlet.2026.218899_bib35","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","article-title":"Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma","volume":"390","author":"Choi","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218899_bib36","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1080\/10717544.2022.2075986","article-title":"Targeting interleukin-13 receptor \u03b12 (IL-13R\u03b12) for glioblastoma therapy with surface functionalized nanocarriers","volume":"29","author":"Liang","year":"2022","journal-title":"Drug Deliv."},{"key":"10.1016\/j.canlet.2026.218899_bib37","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","article-title":"Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","volume":"30","author":"Brown","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218899_bib38","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","article-title":"Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results","volume":"30","author":"Bagley","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218899_bib39","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results","volume":"28","author":"Qi","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218899_bib40","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40364-022-00385-1","article-title":"Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy","volume":"10","author":"Cao","year":"2022","journal-title":"Biomarker Res."},{"key":"10.1016\/j.canlet.2026.218899_bib41","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41575-025-01062-y","article-title":"CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges","volume":"22","author":"Abken","year":"2025","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.canlet.2026.218899_bib42","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218899_bib43","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abm0306","article-title":"A carcinoembryonic antigen-specific cell therapy selectively targets tumor cells with HLA loss of heterozygosity in vitro and in vivo","volume":"14","author":"Sandberg","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218899_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252211953","article-title":"Deciphering folate receptor alphaGene expression and mRNA signatures in ovarian cancer: implications for precision therapies","volume":"25","author":"Kfoury","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218899_bib45","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.3390\/ijms25021046","article-title":"Folate receptor Alpha\u2014A novel approach to cancer therapy","volume":"25","author":"Gonzalez","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218899_bib46","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/resp.14541","article-title":"Overexpression of SMAD7 improves the function of EGFR-targeted human CAR-T cells against non-small-cell lung cancer","volume":"28","author":"Li","year":"2023","journal-title":"Respirology"},{"key":"10.1016\/j.canlet.2026.218899_bib47","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/2326-6066.CIR-19-0293","article-title":"Glypican-3-Specific CAR T cells coexpressing IL15 and IL21 have superior expansion and antitumor activity against hepatocellular carcinoma","volume":"8","author":"Batra","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2026.218899_bib48","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008179","article-title":"Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16","volume":"12","author":"Casey","year":"2024","journal-title":"J. ImmunoTher. Cancer"},{"key":"10.1016\/j.canlet.2026.218899_bib49","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.3390\/cells14171333","article-title":"Engineering of humanized PSMA-Directed CAR T cells for potent and specific elimination of prostate cancer cells","volume":"14","author":"Deller","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2026.218899_bib50","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218899_bib51","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1158\/0008-5472.CAN-24-0195","article-title":"B7-H3-Targeted CAR-V\u03b41T cells exhibit potent broad-spectrum activity against solid tumors","volume":"84","author":"Jiang","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218899_bib52","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2967\/jnumed.125.270400","article-title":"Construction and evaluation of guanylyl cyclase C-Specific antibody for noninvasive diagnosis and targeted therapy of colorectal cancer","volume":"67","author":"Rong","year":"2026","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.canlet.2026.218899_bib53","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41571-025-01051-9","article-title":"Evolving roles of MET as a therapeutic target in NSCLC and beyond","volume":"22","author":"Lee","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218899_bib54","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13045-023-01464-y","article-title":"Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer","volume":"16","author":"Rudin","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2026.218899_bib55","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12943-024-02012-z","article-title":"DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy","volume":"23","author":"Su","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2026.218899_bib56","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s10120-024-01466-w","article-title":"Bemarituzumab as first-line treatment for locally advanced or metastatic gastric\/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial","volume":"27","author":"Wainberg","year":"2024","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.canlet.2026.218899_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.107698","article-title":"Global prevalence of FGFR2b protein overexpression in advanced gastric cancer and gastroesophageal junction cancers: pooled analysis of two bemarituzumab phase III studies","volume":"11","author":"Maron","year":"2026","journal-title":"ESMO Open"},{"key":"10.1016\/j.canlet.2026.218899_bib58","article-title":"EGFR TKIs suppress MUC1 glycosylation through the PI3K\/AKT\/SP1\/C1GALT1 pathway to enhance TnMUC1 CAR-T efficacy in EGFR-mutant NSCLC","volume":"6","author":"Zhou","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.canlet.2026.218899_bib59","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1158\/1078-0432.CCR-24-2172","article-title":"Phase I Study of ROR1-Specific CAR-T cells in advanced hematopoietic and epithelial malignancies","volume":"31","author":"Jaeger-Ruckstuhl","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218899_bib60","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg9721","article-title":"EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors","volume":"9","author":"Li","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.canlet.2026.218899_bib61","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s00262-025-04267-x","article-title":"Preclinical evaluation of CAR-T cell immunotherapy with a fully human EpCAM-specific scFv against pancreatic cancer","volume":"75","author":"Fan","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2026.218899_bib62","doi-asserted-by":"crossref","DOI":"10.1172\/JCI142030","article-title":"Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes","volume":"131","author":"Roselli","year":"2021","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2026.218899_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1304765","article-title":"Geometric parameters that affect the behavior of logic-gated CAR T cells","volume":"15","author":"Partin","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218899_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114720","article-title":"Advancing immunotherapy with innovations in CAR-M engineering for cancer treatment","volume":"156","author":"Lee","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.canlet.2026.218899_bib65","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abl3995","article-title":"Size-dependent activation of CAR-T cells","volume":"7","author":"Xiao","year":"2022","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.canlet.2026.218899_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.864868","article-title":"Programmable attenuation of antigenic sensitivity for a nanobody-based EGFR chimeric antigen receptor through Hinge domain truncation","volume":"13","author":"McComb","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218899_bib67","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41577-024-01093-7","article-title":"From TCR fundamental research to innovative chimeric antigen receptor design","volume":"25","author":"Minguet","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2026.218899_bib68","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/med.21818","article-title":"The antigen-binding moiety in the driver's seat of CARs","volume":"42","author":"Hanssens","year":"2022","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.canlet.2026.218899_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102931","article-title":"CAR-T design: elements and their synergistic function","volume":"58","author":"Jayaraman","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.canlet.2026.218899_bib70","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/s42003-024-06770-w","article-title":"CD28 Hinge used in chimeric antigen receptor (CAR) T-cells exhibits local structure and conformational exchange amidst global disorder","volume":"7","author":"Folimonova","year":"2024","journal-title":"Commun. Biol."},{"key":"10.1016\/j.canlet.2026.218899_bib71","article-title":"CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity","volume":"15","author":"Kong","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218899_bib72","article-title":"CAR-M therapy in the era of tumor immunotherapy: current research progress and engineering strategies","volume":"16","author":"Yang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218899_bib73","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41698-025-01170-7","article-title":"CAR-macrophages in solid tumors: promise, progress, and prospects","volume":"9","author":"Alrehaili","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.canlet.2026.218899_bib74","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1186\/s12967-025-07115-9","article-title":"New power in cancer immunotherapy: the rise of chimeric antigen receptor macrophage (CAR-M)","volume":"23","author":"Jing","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218899_bib75","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.639818","article-title":"The CD28-Transmembrane domain mediates chimeric antigen receptor heterodimerization with CD28","volume":"12","author":"Muller","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218899_bib76","doi-asserted-by":"crossref","first-page":"4732","DOI":"10.1038\/s41467-023-40303-z","article-title":"Complementarity-determining region clustering may cause CAR-T cell dysfunction","volume":"14","author":"Sar\u00e9n","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218899_bib77","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/cac2.70053","article-title":"Harnessing chimeric antigen receptor macrophages against solid tumors","volume":"45","author":"Wang","year":"2025","journal-title":"Cancer Commun."},{"key":"10.1016\/j.canlet.2026.218899_bib78","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jconrel.2024.11.064","article-title":"An engineered \u03b11\u03b21 integrin-mediated Fc\u03b3RI signaling component to control enhanced CAR macrophage activation and phagocytosis","volume":"377","author":"Du","year":"2025","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.canlet.2026.218899_bib79","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s00262-024-03759-6","article-title":"Engineered CD147-CAR macrophages for enhanced phagocytosis of cancers","volume":"73","author":"Chupradit","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2026.218899_bib80","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.91999.3","article-title":"Expression of modified Fc\u03b3RI enables myeloid cells to elicit robust tumor-specific cytotoxicity","volume":"12","author":"Farhat-Younis","year":"2024","journal-title":"eLife"},{"key":"10.1016\/j.canlet.2026.218899_bib81","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12943-025-02538-w","article-title":"Synergistic innate-adaptive immunity by NKG2D-specific CAR-macrophages drives durable remission in hepatocellular carcinoma","volume":"25","author":"Zhao","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2026.218899_bib82","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/imr.13313","article-title":"ITAM-based receptors in natural killer cells","volume":"323","author":"Aguilar","year":"2024","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.canlet.2026.218899_bib83","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1200\/JCO-24-02424","article-title":"Results from first-in-human phase I Study of a novel CD19-1XX chimeric antigen receptor with calibrated signaling in large B-Cell lymphoma","volume":"43","author":"Park","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218899_bib84","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41392-024-02096-5","article-title":"Chimeric antigen receptor with novel intracellular modules improves antitumor performance of T cells","volume":"10","author":"Wang","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2026.218899_bib85","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.36688","article-title":"Chimeric antigen receptors that trigger phagocytosis","volume":"7","author":"Morrissey","year":"2018","journal-title":"eLife"},{"key":"10.1016\/j.canlet.2026.218899_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105390","article-title":"Homology-independent targeted insertion-mediated derivation of M1-biased macrophages harbouring Megf10 and CD3\u03b6 from human pluripotent stem cells","volume":"109","author":"Zhen","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.canlet.2026.218899_bib87","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.jare.2024.12.043","article-title":"Targeting macrophages in cancer immunotherapy: frontiers and challenges","volume":"76","author":"Liu","year":"2025","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.canlet.2026.218899_bib88","doi-asserted-by":"crossref","first-page":"8623","DOI":"10.1038\/ncomms9623","article-title":"Phosphoinositide 3-kinase enables phagocytosis of large particles by terminating actin assembly through Rac\/Cdc42 GTPase-activating proteins","volume":"6","author":"Schlam","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218899_bib89","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41590-023-01687-8","article-title":"A second-generation M1-polarized CAR macrophage with antitumor efficacy","volume":"25","author":"Lei","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2026.218899_bib90","doi-asserted-by":"crossref","first-page":"994","DOI":"10.3390\/cells11060994","article-title":"Ex vivo generation of CAR macrophages from hematopoietic stem and progenitor cells for use in cancer therapy","volume":"11","author":"Paasch","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2026.218899_bib91","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/path.5585","article-title":"Chimeric antigen receptor-modified macrophages trigger systemic anti-tumour immunity","volume":"253","author":"Niu","year":"2021","journal-title":"J. Pathol."},{"key":"10.1016\/j.canlet.2026.218899_bib92","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/s41416-019-0578-3","article-title":"Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix","volume":"121","author":"Zhang","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218899_bib93","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218899_bib94","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abm1463","article-title":"Pooled screening of CAR T cells identifies diverse immune signaling domains for next-generation immunotherapies","volume":"14","author":"Goodman","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218899_bib95","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41467-025-67674-9","article-title":"Intraperitoneal programming of tailored CAR macrophages via mRNA lipid nanoparticle to boost cancer immunotherapy","volume":"17","author":"Gu","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218899_bib96","doi-asserted-by":"crossref","DOI":"10.3390\/ijms27031292","article-title":"Targeting macrophages in immunotherapy: the ascent of CAR-Macrophages","volume":"27","author":"Nadella","year":"2026","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218899_bib100","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13045-024-01635-5","article-title":"A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy","volume":"17","author":"Li","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2026.218899_bib101","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41467-024-55770-1","article-title":"Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models","volume":"16","author":"Pierini","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218899_bib102","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s40164-025-00654-3","article-title":"Addressing graft-versus-host disease in allogeneic cell-based immunotherapy for cancer","volume":"14","author":"Lyu","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2026.218899_bib103","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13045-026-01792-9","article-title":"Optimizing next-generation CAR-macrophages against solid tumors: challenges and potential strategies","volume":"19","author":"Chen","year":"2026","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2026.218899_bib104","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007705","article-title":"Scalable generation of functional human iPSC-derived CAR-macrophages that efficiently eradicate CD19-positive leukemia","volume":"11","author":"Abdin","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218899_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.stemcr.2025.102515","article-title":"Engineering the next generation of allogeneic CAR cells: iPSCs as a scalable and editable platform","volume":"20","author":"Fang","year":"2025","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.canlet.2026.218899_bib106","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/path.70063","article-title":"Human induced pluripotent stem cell-derived chimeric antigen receptor-macrophages eradicate IL-13R\u03b12-positive solid tumors","volume":"269","author":"Yang","year":"2026","journal-title":"J. Pathol."},{"key":"10.1016\/j.canlet.2026.218899_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2025.115713","article-title":"iPSC-derived T cells and macrophages: manufacturing and next-generation application approaches","volume":"227","author":"Bas\u00edlio-Queir\u00f3s","year":"2025","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.canlet.2026.218899_bib108","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13046-025-03359-x","article-title":"Are monocytes a preferable option to develop myeloid cell-based therapies for solid tumors?","volume":"44","author":"Bhatia","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218899_bib97","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.stem.2024.04.012","article-title":"Activating innate immune responses repolarizes hPSC-derived CAR macrophages to improve anti-tumor activity","volume":"31","author":"Shen","year":"2024","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.canlet.2026.218899_bib98","doi-asserted-by":"crossref","first-page":"7166","DOI":"10.1038\/s41467-025-62506-2","article-title":"Lung metastasis and recurrence is mitigated by CAR macrophages, in-situ-generated from mRNA delivered by small extracellular vesicles","volume":"16","author":"Xiao","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218899_bib99","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2426724122","article-title":"In vivo generation of CAR macrophages via the enucleated mesenchymal stem cell delivery system for glioblastoma therapy","volume":"122","author":"Zhou","year":"2025","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2026.218899_bib109","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1068625","article-title":"Differences in the phenotypes and transcriptomic signatures of chimeric antigen receptor T lymphocytes manufactured via electroporation or lentiviral transfection","volume":"14","author":"Niu","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218899_bib110","doi-asserted-by":"crossref","unstructured":"Annunziata CM, Ghobadi A, Pennella EJ, et al. Feasibility and preliminary safety and efficacy of first-in-human intraperitoneal delivery of MCY-M11, anti-human-mesothelin CAR mRNA transfected into peripheral blood mononuclear cells, for ovarian cancer and malignant peritoneal mesothelioma. J. Clin. Oncol..38:3014\u20133014..","DOI":"10.1200\/JCO.2020.38.15_suppl.3014"},{"key":"10.1016\/j.canlet.2026.218899_bib111","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40820-020-00523-0","article-title":"Intracellular delivery of mRNA in adherent and suspension cells by vapor nanobubble photoporation","volume":"12","author":"Raes","year":"2020","journal-title":"Nano-Micro Lett."},{"key":"10.1016\/j.canlet.2026.218899_bib112","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.omtn.2021.08.014","article-title":"Cas9 RNP transfection by vapor nanobubble photoporation for ex vivo cell engineering","volume":"25","author":"Raes","year":"2021","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.canlet.2026.218899_bib113","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26189199","article-title":"A bioactive lipid nanoparticle integrating arachidonic acid enables high-efficiency mRNA delivery and potent CAR-Macrophage engineering","volume":"26","author":"Fu","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218899_bib114","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1021\/acsnano.3c10109","article-title":"mRNA-Laden lipid-nanoparticle-enabled in situ CAR-Macrophage engineering for the eradication of multidrug-resistant bacteria in a sepsis mouse model","volume":"18","author":"Tang","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.canlet.2026.218899_bib115","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202312038","article-title":"Oxidized mRNA lipid nanoparticles for in situ chimeric antigen receptor Monocyte engineering","volume":"34","author":"Mukalel","year":"2024","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.canlet.2026.218899_bib116","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s12026-026-09762-6","article-title":"Innovative biomaterial solutions for enhancing the efficacy of tumor immunotherapy","volume":"74","author":"Zhu","year":"2026","journal-title":"Immunol. Res."},{"key":"10.1016\/j.canlet.2026.218899_bib117","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41551-023-01058-6","article-title":"AAV-mediated delivery of a sleeping Beauty transposon and an mRNA-encoded transposase for the engineering of therapeutic immune cells","volume":"8","author":"Ye","year":"2024","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.canlet.2026.218899_bib118","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252413685","article-title":"Current non-viral-based strategies to manufacture CAR-T cells","volume":"25","author":"Gehrke","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218899_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101425","article-title":"Generation and GMP scale-up of human CAR-T cells using non-viral sleeping Beauty transposons for B cell malignances","volume":"33","author":"Diez","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.canlet.2026.218899_bib120","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109207","article-title":"Targeted delivery of CRISPR-Cas9 and transgenes enables complex immune cell engineering","volume":"35","author":"Hamilton","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2026.218899_bib121","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1186\/s12967-025-07183-x","article-title":"Preventing secondary primary malignancies (SPMs) in CAR-T cell therapy through site-specific transgene integration into genomic safe harbors (GSHs)","volume":"23","author":"Safarzadeh Kozani","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218899_bib122","doi-asserted-by":"crossref","DOI":"10.3390\/cells15010081","article-title":"Human genome safe Harbor sites: a comprehensive review of criteria, discovery, features, and applications","volume":"15","author":"Ahmed","year":"2026","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2026.218899_bib123","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12967-023-04061-2","article-title":"M1 polarization enhances the antitumor activity of chimeric antigen receptor macrophages in solid tumors","volume":"21","author":"Huo","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218899_bib124","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13010099","article-title":"Optimized method to generate well-characterized macrophages from induced pluripotent stem cells","volume":"13","author":"Hai","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.canlet.2026.218899_bib125","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70374","article-title":"Chimeric antigen receptor-macrophage therapy enters the Clinic: the first-in-human trial for HER2+ solid tumors","volume":"6","author":"Ma","year":"2025","journal-title":"MedComm"},{"key":"10.1016\/j.canlet.2026.218899_bib126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-024-00703-9","article-title":"Lentivirus-based production of human chimeric antigen receptor macrophages from peripheral blood","volume":"13","author":"Choi","year":"2025","journal-title":"Biomarker Res."},{"key":"10.1016\/j.canlet.2026.218899_bib127","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13030396","article-title":"The ins and outs of messenger RNA electroporation for physical gene delivery in immune cell-based therapy","volume":"13","author":"Campillo-Davo","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.canlet.2026.218899_bib128","doi-asserted-by":"crossref","DOI":"10.20517\/microstructures.2024.32","article-title":"Mechanoimmunomodulation-based strategy on advancing tissue-engineered nanotopographic structures","volume":"5","author":"Ao","year":"2025","journal-title":"Microstructures"},{"key":"10.1016\/j.canlet.2026.218899_bib129","doi-asserted-by":"crossref","DOI":"10.20517\/microstructures.2024.172","article-title":"Advances in mRNA-LNP lung-targeted delivery strategies","volume":"5","author":"Liu","year":"2025","journal-title":"Microstructures"},{"key":"10.1016\/j.canlet.2026.218899_bib130","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jconrel.2023.07.021","article-title":"Dual mRNA co-delivery for in situ generation of phagocytosis-enhanced CAR macrophages augments hepatocellular carcinoma immunotherapy","volume":"360","author":"Yang","year":"2023","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.canlet.2026.218899_bib131","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.jare.2026.01.070","article-title":"Biomimetic and personalized nanovaccines in cancer immunotherapy: design innovations, translational challenges, and future directions","volume":"88","author":"Xu","year":"2026","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.canlet.2026.218899_bib132","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.chom.2025.12.014","article-title":"Engineered probiotics recruit CAR macrophages and establish immune memory to eradicate heterogeneous glioblastoma in mice","volume":"34","author":"Zhang","year":"2026","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.canlet.2026.218899_bib133","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.canlet.2026.218899_bib134","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2302997120","article-title":"Targeted evolution of adeno-associated virus capsids for systemic transgene delivery to microglia and tissue-resident macrophages","volume":"120","author":"Young","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2026.218899_bib135","article-title":"AAV vectors for specific and efficient gene expression in microglia","volume":"5","author":"Aoki","year":"2025","journal-title":"Cell Rep. Methods"},{"key":"10.1016\/j.canlet.2026.218899_bib136","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310447","article-title":"Transcriptomic analysis reveals the inability of recombinant AAV8 to activate human monocyte-derived dendritic cells","volume":"24","author":"Masri","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218899_bib137","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1161\/CIRCRESAHA.125.326716","article-title":"CAR macrophages engineered in vivo for attenuating myocardial ischemia-reperfusion injury","volume":"137","author":"Du","year":"2025","journal-title":"Circ. Res."},{"key":"10.1016\/j.canlet.2026.218899_bib138","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12943-026-02597-7","article-title":"Therapeutic reprogramming of tumour-associated macrophages in pancreatic cancer using a cytotoxic CCR2-targeted nanotheranostic","volume":"25","author":"Somani","year":"2026","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2026.218899_bib139","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202502151","article-title":"CCR2-Engineered macrophage membrane-coated metal-polyphenol nanozyme to enhance antioxidation activity for inhibiting the atherosclerotic progression","volume":"15","author":"Yan","year":"2026","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.canlet.2026.218899_bib140","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2314747121","article-title":"Precision treatment of viral pneumonia through macrophage-targeted lipid nanoparticle delivery","volume":"121","author":"Zhao","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2026.218899_bib141","doi-asserted-by":"crossref","first-page":"8203","DOI":"10.1038\/s41467-024-52500-5","article-title":"Glypican-3-targeted macrophages delivering drug-loaded exosomes offer efficient cytotherapy in mouse models of solid tumours","volume":"15","author":"Liu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218899_bib142","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s44222-025-00277-7","article-title":"Extracellular vesicles for the delivery of gene therapy","volume":"3","author":"Di Ianni","year":"2025","journal-title":"Nat. Rev. Bioeng."},{"key":"10.1016\/j.canlet.2026.218899_bib143","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.3390\/ijms27052163","article-title":"Harnessing CAR-Extracellular vesicles for next-generation cancer immunotherapy","volume":"27","author":"Chelvaretnam","year":"2026","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218899_bib144","doi-asserted-by":"crossref","first-page":"8175","DOI":"10.1038\/s41598-026-39406-6","article-title":"Optimization of THP-1-CAR monocytes utilizing CD32a signaling phagocytosis for antigen-specific T cell activation","volume":"16","author":"Hong","year":"2026","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2026.218899_bib145","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adp4008","article-title":"Dissecting the role of CAR signaling architectures on T cell activation and persistence using pooled screens and single-cell sequencing","volume":"11","author":"Castellanos-Rueda","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.canlet.2026.218899_bib146","doi-asserted-by":"crossref","DOI":"10.1007\/s12038-024-00441-y","article-title":"Harnessing the innate immune system by revolutionizing macrophage-mediated cancer immunotherapy","volume":"49","author":"Reghu","year":"2024","journal-title":"J Biosci"},{"key":"10.1016\/j.canlet.2026.218899_bib147","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/imr.13301","article-title":"Decoding immunogenic cell death from a dendritic cell perspective","volume":"321","author":"Janssens","year":"2024","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.canlet.2026.218899_bib148","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1186\/s12967-023-04479-8","article-title":"The application of HER2 and CD47 CAR-macrophage in ovarian cancer","volume":"21","author":"Chen","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218899_bib149","doi-asserted-by":"crossref","DOI":"10.1002\/mog2.70036","article-title":"Enhancing PD-1 blockade with CAR-Macrophage therapy in HER2+ solid tumors","volume":"4","author":"Ma","year":"2025","journal-title":"MedComm \u2013 Oncology"},{"key":"10.1016\/j.canlet.2026.218899_bib150","volume":"120","author":"Lax","year":"2023"},{"key":"10.1016\/j.canlet.2026.218899_bib151","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s40164-025-00696-7","article-title":"CD47 antibody-armed oncolytic adenovirus promotes chimeric antigen receptor macrophage phagocytosis and antitumor immunity","volume":"14","author":"Qi","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2026.218899_bib152","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1158\/0008-5472.CAN-19-3038","article-title":"Allosteric inhibition of SHP2 stimulates antitumor immunity by transforming the immunosuppressive environment","volume":"80","author":"Quintana","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218899_bib153","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107126","article-title":"CSF1R inhibition reprograms tumor-associated macrophages to potentiate anti-PD-1 therapy efficacy against colorectal cancer","volume":"202","author":"Lv","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.canlet.2026.218899_bib154","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202417778","article-title":"CaMKK2 regulates macrophage polarization induced by matrix stiffness: implications for shaping the immune response in stiffened tissues","volume":"12","author":"Guan","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.canlet.2026.218899_bib155","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/s41419-024-07267-4","article-title":"Inhibition of furin in CAR macrophages directs them toward a proinflammatory phenotype and enhances their antitumor activities","volume":"15","author":"Ziane-Chaouche","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2026.218899_bib156","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/s41423-024-01220-3","article-title":"Silencing of SIRP\u03b1 enhances the antitumor efficacy of CAR-M in solid tumors","volume":"21","author":"Zhang","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.canlet.2026.218899_bib157","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41392-025-02325-5","article-title":"Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments","volume":"10","author":"Xu","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2026.218899_bib158","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2024.155558","article-title":"Baicalein alleviates cardiomyocyte death in EAM mice by inhibiting the JAK-STAT1\/4 signalling pathway","volume":"128","author":"Wang","year":"2024","journal-title":"Phytomedicine"},{"key":"10.1016\/j.canlet.2026.218899_bib159","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1182\/bloodadvances.2018017566","article-title":"HIF prolyl hydroxylase inhibitor FG-4497 enhances mouse hematopoietic stem cell mobilization via VEGFR2\/KDR","volume":"3","author":"Bisht","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.canlet.2026.218899_bib160","doi-asserted-by":"crossref","first-page":"6261","DOI":"10.1038\/s41467-025-61560-0","article-title":"YY1 enhances HIF-1\u03b1 stability in tumor-associated macrophages to suppress anti-tumor immunity of prostate cancer in mice","volume":"16","author":"Li","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218899_bib161","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1002\/eji.202048944","article-title":"Fa(c)t checking: how fatty acids shape metabolism and function of macrophages and dendritic cells","volume":"51","author":"Almeida","year":"2021","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.canlet.2026.218899_bib162","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-03446-1","article-title":"Metabolomic reprogramming of the tumor microenvironment by dual arginase inhibitor OATD-02 boosts anticancer immunity","volume":"15","author":"Grzybowski","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2026.218899_bib163","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/s13046-023-02888-7","article-title":"Ginseng-derived nanoparticles reprogram macrophages to regulate arginase-1 release for ameliorating T cell exhaustion in tumor microenvironment","volume":"42","author":"Lv","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218899_bib164","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00281-025-01038-9","article-title":"Arginine metabolism in myeloid cells in health and disease","volume":"47","author":"Karadima","year":"2025","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.canlet.2026.218899_bib165","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2147\/ITT.S494550","article-title":"The regulatory network of transcription factors in macrophage polarization","volume":"14","author":"Liu","year":"2025","journal-title":"ImmunoTargets Ther."},{"key":"10.1016\/j.canlet.2026.218899_bib166","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113430","article-title":"Macrophage autophagy deficiency-induced CEBPB accumulation alleviates atopic dermatitis via impairing M2 polarization","volume":"42","author":"Zhu","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2026.218899_bib167","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2026.112638","article-title":"IRF5 promotes the polarization of M1 macrophages and aggravates pulmonary inflammation in connective tissue disease-related interstitial lung disease (CTD-ILD) by regulating IFN-\u03b2","volume":"146","author":"Chen","year":"2026","journal-title":"Cell. Signal."},{"key":"10.1016\/j.canlet.2026.218899_bib168","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.freeradbiomed.2023.03.014","article-title":"Irisin drives macrophage anti-inflammatory differentiation via JAK2-STAT6-dependent activation of PPAR\u03b3 and Nrf2 signaling","volume":"201","author":"Tu","year":"2023","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.canlet.2026.218899_bib169","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1038\/s41388-020-01636-x","article-title":"HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression","volume":"40","author":"Li","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2026.218899_bib170","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13115","article-title":"Role of the CCL2-CCR2 signalling axis in cancer: mechanisms and therapeutic targeting","volume":"54","author":"Xu","year":"2021","journal-title":"Cell Prolif."},{"key":"10.1016\/j.canlet.2026.218899_bib171","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12964-020-00589-8","article-title":"CCL2\/CCR2 signaling in cancer pathogenesis","volume":"18","author":"Hao","year":"2020","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.canlet.2026.218899_bib172","article-title":"CC chemokines in a tumor: a review of pro-cancer and anti-cancer properties of receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 ligands","volume":"21","author":"Korbecki","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218899_bib173","article-title":"Chemokine receptor engineering of T cells with CXCR2 improves homing towards subcutaneous human melanomas in xenograft mouse model","volume":"7","author":"Idorn","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.canlet.2026.218899_bib174","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1038\/s41590-026-02615-2","article-title":"Neutrophil-integrated syncytial CAR macrophage for cancer immunotherapy","volume":"27","author":"Tian","year":"2026","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2026.218899_bib175","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41416-023-02319-6","article-title":"Efficacy evaluation of chimeric antigen receptor-modified human peritoneal macrophages in the treatment of gastric cancer","volume":"129","author":"Dong","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218899_bib176","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS2682","article-title":"A phase 1, first-in-human study of autologous monocytes engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2-overexpressing solid tumors","volume":"42","author":"Abdou","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218899_bib177","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz253.133","volume":"30","author":"Annunziata","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2026.218899_bib178","article-title":"194 pre-clinical development of CT-1119, a mesothelin targeting chimeric antigen receptor macrophage (CAR-M), for solid tumor immunotherapy","volume":"10","author":"Anderson","year":"2022","journal-title":"J. ImmunoTher. Cancer"},{"key":"10.1016\/j.canlet.2026.218899_bib179","doi-asserted-by":"crossref","first-page":"7495","DOI":"10.1038\/s41467-026-74162-1","article-title":"In situ reprogramming of CAR-alveolar macrophages via liposomal nanomedicine for lung cancer immunotherapy","volume":"17","author":"Li","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218899_bib180","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101250","article-title":"CAR-T cell manufacturing landscape\u2014Lessons from the past decade and considerations for early clinical development","volume":"32","author":"Dias","year":"2024","journal-title":"Mol. Ther., Methods Clin. Dev."},{"key":"10.1016\/j.canlet.2026.218899_bib181","first-page":"42221","article-title":"Ultrasound-Activatable lipid nanoplatform for region-confined innate immune stimulation and mRNA vaccination therapy of cancer","volume":"147","author":"Chen","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.canlet.2026.218899_bib182","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1021\/acsabm.0c00242","article-title":"Matrix metalloproteinase-responsive PEGylated lipid nanoparticles for controlled drug delivery in the treatment of rheumatoid arthritis","volume":"3","author":"He","year":"2020","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.canlet.2026.218899_bib183","first-page":"333","article-title":"Focused evaluation of the roles of macrophages in chimeric antigen receptor (CAR) T cell therapy associated cytokine release syndrome","volume":"19","author":"Guo","year":"2021","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.canlet.2026.218899_bib184","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40164-020-00171-5","article-title":"Macrophage, the potential key mediator in CAR-T related CRS","volume":"9","author":"Hao","year":"2020","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2026.218899_bib185","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2026.218257","article-title":"Programmable Smart CAR-T design: a new paradigm in precision immunotherapy driven by logic gates, conditional activation, allogeneic strategies, and artificial intelligence","volume":"640","author":"Wen","year":"2026","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218899_bib186","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/gt.2011.195","article-title":"Evaluation of macrophage-specific promoters using lentiviral delivery in mice","volume":"19","author":"Levin","year":"2012","journal-title":"Gene Ther."},{"key":"10.1016\/j.canlet.2026.218899_bib187","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/ni.2236","article-title":"SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates","volume":"13","author":"Lahouassa","year":"2012","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2026.218899_bib188","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3390\/cells15030238","article-title":"Irf5 knockdown in bone marrow-derived macrophages favors M1-to-M2 transition","volume":"15","author":"Petrova","year":"2026","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2026.218899_bib189","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/s41467-023-37785-2","article-title":"Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice","volume":"14","author":"Hu","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218899_bib190","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s00262-025-04032-0","article-title":"Targeted CD47 checkpoint blockade using a mesothelin-directed antibody construct for enhanced solid tumor-specific immunotherapy","volume":"74","author":"Reischer","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2026.218899_bib191","doi-asserted-by":"crossref","first-page":"5778","DOI":"10.1038\/s41467-023-41470-9","article-title":"Metabolic Reprogramming via ACOD1 depletion enhances function of human induced pluripotent stem cell-derived CAR-macrophages in solid tumors","volume":"14","author":"Wang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218899_bib192","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jconrel.2017.03.028","article-title":"Optimized biodegradable polymeric reservoir-mediated local and sustained co-delivery of dendritic cells and oncolytic adenovirus co-expressing IL-12 and GM-CSF for cancer immunotherapy","volume":"259","author":"Oh","year":"2017","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.canlet.2026.218899_bib193","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00428-019-02624-7","article-title":"Expression of the potential therapeutic target claudin-18.2 is frequently decreased in gastric cancer: results from a large Caucasian cohort study","volume":"475","author":"Dottermusch","year":"2019","journal-title":"Virchows Arch."},{"key":"10.1016\/j.canlet.2026.218899_bib194","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.semcancer.2023.02.007","article-title":"Artificial intelligence in cancer immunotherapy: applications in neoantigen recognition, antibody design and immunotherapy response prediction","volume":"91","author":"Li","year":"2023","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.canlet.2026.218899_bib195","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41392-022-00994-0","article-title":"Artificial intelligence in cancer target identification and drug discovery","volume":"7","author":"You","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2026.218899_bib196","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41422-024-00936-1","article-title":"CAR-Toner: an AI-driven approach for CAR tonic signaling prediction and optimization","volume":"34","author":"Qiu","year":"2024","journal-title":"Cell Res."},{"key":"10.1016\/j.canlet.2026.218899_bib197","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216610","article-title":"Advanced insights on tumor-associated macrophages revealed by single-cell RNA sequencing: the intratumor heterogeneity, functional phenotypes, and cellular interactions","volume":"584","author":"Yang","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218899_bib198","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114421","article-title":"Cellular kinetics: a clinical and computational review of CAR-T cell pharmacology","volume":"188","author":"Qi","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.canlet.2026.218899_bib199","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtbi.2025.112263","article-title":"Mathematical model suggests current CAR-macrophage dosage is efficient to low pre-infusion tumour burden but refractory to high tumour burden","volume":"616","author":"Xu","year":"2026","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.canlet.2026.218899_bib200","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abe7378","article-title":"SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma","volume":"13","author":"Choe","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218899_bib201","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13046-020-01572-4","article-title":"Extended half-life target module for sustainable UniCAR T-cell treatment of STn-expressing cancers","volume":"39","author":"Loureiro","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218899_bib202","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1182\/blood.2020009759","article-title":"Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed\/refractory AML","volume":"137","author":"Wermke","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2026.218899_bib203","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.matbio.2023.04.002","article-title":"Tumor-associated fibrosis impairs the response to immunotherapy","volume":"119","author":"Naik","year":"2023","journal-title":"Matrix Biol."},{"key":"10.1016\/j.canlet.2026.218899_bib204","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41588-024-01998-y","article-title":"Multi-omic profiling highlights factors associated with resistance to immuno-chemotherapy in non-small-cell lung cancer","volume":"57","author":"Yan","year":"2025","journal-title":"Nat. Genet."},{"key":"10.1016\/j.canlet.2026.218899_bib205","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004076","article-title":"Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients na\u00efve or experienced for immune checkpoint blockade","volume":"10","author":"Gomez-Roca","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218899_bib206","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.jare.2025.01.004","article-title":"Exploring CAR-macrophages in non-tumor diseases: therapeutic potential beyond cancer","volume":"77","author":"Chen","year":"2025","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.canlet.2026.218899_bib207","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41586-020-2403-9","article-title":"Senolytic CAR T cells reverse senescence-associated pathologies","volume":"583","author":"Amor","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218899_bib208","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1161\/CIRCRESAHA.124.325212","article-title":"CAR-Macrophage therapy alleviates myocardial ischemia-reperfusion injury","volume":"135","author":"Wang","year":"2024","journal-title":"Circ. Res."},{"key":"10.1016\/j.canlet.2026.218899_bib209","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.175015","article-title":"Chimeric antigen receptor macrophages target and resorb amyloid plaques","volume":"9","author":"Kim","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.canlet.2026.218899_bib210","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40035-025-00518-0","article-title":"Attenuating \u03b1-synuclein pathology in mice with in situ engineered astrocytes","volume":"14","author":"Du","year":"2025","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.canlet.2026.218899_bib211","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13072-025-00575-9","article-title":"Crosstalk between metabolism and epigenetics during macrophage polarization","volume":"18","author":"Zhang","year":"2025","journal-title":"Epigenetics Chromatin"},{"key":"10.1016\/j.canlet.2026.218899_bib212","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2024.102610","article-title":"Lipid nanoparticles produce chimeric antigen receptor macrophages (CAR-M) in situ for the treatment of solid tumors","volume":"61","author":"Zhou","year":"2025","journal-title":"Nano Today"},{"key":"10.1016\/j.canlet.2026.218899_bib213","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcyt.2026.102538","article-title":"Reproducible generation OF CAR macrophages from stem and progenitor cell sources using a dual-signalling anti-CEA CAR","volume":"28","author":"Alrehaili","year":"2026","journal-title":"Cytotherapy"},{"key":"10.1016\/j.canlet.2026.218899_bib214","doi-asserted-by":"crossref","DOI":"10.20517\/microstructures.2025.71","article-title":"Bench-to-bedside translation of podophyllotoxin-based nanomedicines for cancer treatment: utopias and reality?","volume":"5","author":"Wang","year":"2025","journal-title":"Microstructures"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526006634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526006634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:37:08Z","timestamp":1793324228000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526006634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":214,"alternative-id":["S0304383526006634"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218899","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Next-generation CAR-macrophage therapies: Design principles and advances in cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218899","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218899"}}